HOME >> BIOLOGY >> NEWS
Copper chelation is a promising new therapy for clogged arteries

Researchers at the Maine Medical Center Research Institute (MMCRI) in Scarborough, Maine, announce their discovery that the renarrowing of arteries following balloon angioplasty can be halted by copper chelation therapy. Preventing the function of copper in the body stops arteries from reclogging following the mechanical stress of removing arterial obstructions through angioplasty. The therapy works by limiting the cellular export of growth factors and cytokines involved in this process.

"This represents a major contribution to medical science," said Kenneth A. Ault, M.D., Director of MMCRI. "This finding could be ready for widespread clinical use in humans in a very few years."

Thomas Maciag, Ph.D. and his team of scientists at MMCRI's Center for Molecular Medicine led a team of investigators from the Netherlands and Bulgaria, including scientists from Dartmouth Hitchcock Medical Center. They discovered that the function of copper is necessary for restenosis, and that after angioplasty or stent surgery is performed, the presence of copper in cells of the artery enables the regrowth of cells from within the injured vessel. This process recloses the artery in about 30% of cases, requiring more surgery with its inherent expense and risk to the patient.

"Maciag and colleagues appear to have solved a long-lingering paradox in the field of growth factor biology," commented Dr. Elazer R. Edelman, Director of Harvard-MIT Biomedical Engineering Center in Cambridge, Massachusetts. "Their imaginative work may provide novel treatment modalities for a range of critical diseases."

This work was published in a preeminent journal, Proceedings of the National Academy of Sciences, May 27, 2003, in the paper "Copper Chelation Represses the Vascular Response to Injury."

The scientists at MMCRI found that the commonly available reagent TTM (tetrathiomolybdate), which is a specific copper chelator, stopped inflammation and growth of the unwanted new ti
'"/>

Contact: Wayne L. Clark
clarkw@mmc.org
207-871-2196
Maine Medical Center
22-May-2003


Page: 1 2

Related biology news :

1. Copper may play role in starving cancer to standstill
2. Copper is crucial for embryonic deveopment, say U-M scientists
3. Tobacco promising factory for biopharmaceuticals
4. Gene therapy with growth factor seems promising therapy for incurable muscle disorder ALS
5. The search for a safer smallpox vaccine: New data released on promising candidate
6. New software developed at Rensselaer predicts promising ingredients for new drugs
7. Study points to a promising new test for myelodysplasia, a blood disorder often leading to leukemia
8. Protease-inhibitor cocktail protects, increases anti-microbial action of promising new peptide
9. Researchers begin promising new trial to fight colorectal cancer
10. Inhibition of insulin-like growth factor receptor-1 as promising anticancer therapeutic
11. Puffer fish biotoxin provides promising relief in cancer pain

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Copper chelation promising new therapy for clogged arteries

(Date:5/18/2013)... Research presented today at Digestive Disease Week (DDW) ... about the impact of coffee on autoimmune disease and ... consumption recently has been associated with reduced risk of ... more cups of java each month also correlate with ... at the Mayo Clinic, Rochester, MN, linked coffee consumption ...
(Date:5/18/2013)... An increasing number of U.S. children are ... according to research presented at Digestive Disease Week ... researchers at the Cleveland Clinic Children,s Hospital found ... exhaled breath compared to their lean counterparts. The ... that can be correlated to potential complications associated ...
(Date:5/17/2013)... insects provide the white noise of the South, but the ... the Southern air hangs heavy from the humidity and the ... than 140 species of frogs, toads and salamanders, is the ... ponds and swamps are the auditorium for their symphonic choruses, ... Monitoring Initiative, or ARMI, have front-row seats. , ...
Breaking Biology News(10 mins):Coffee consumption associated with reduced risk of autoimmune liver disease 2New research identifies risks, interventions for children's GI health 2New research identifies risks, interventions for children's GI health 3Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4
(Date:5/21/2013)... TX (PRWEB) May 21, 2013 Smarter ... outdoor security solutions, today announced that Genzyme, a Sanofi ... units of Door Detective® CL for a multi-use facility ... installed in four other Genzyme buildings, this latest order ... with the tailgate detection device improving doorway ...
(Date:5/21/2013)... 2013  MacroGenics, Inc. today announced that an ... an Fc-modified chimeric monoclonal antibody (MAb), in patients ... will be presented at the 2013 Annual Meeting ... the Developmental Therapeutics - Immunotherapy Oral Abstract Session ... PM.  The presentation will describe the results of ...
(Date:5/21/2013)... May 21, 2013 NANONEX CORPORATION, ... solutions , today announced the successful delivery and ... system, the NX-M200B, to a major Japanese manufacturing ... a fully-automated, production-ready, advanced nanoimprint lithography tool that ... wafer and substrate sizes and types. Based on ...
(Date:5/21/2013)... 2013 PathoGenetix, Inc., a commercial-stage developer ... announced today that it has successfully identified and strain ... obtained from the Centers for Disease Control and Prevention ... The findings are detailed in a poster ... for Microbiology in Denver on Monday. , The 250 ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 2New Genotyping System Identifies Pathogenic E. coli Outbreak Strains 3
Cached News: